About Q-Line Biotech IPO
Q-line Biotech IPO Details
Q-line Biotech IPO is a 100% book-built issue of up to ₹214 crore, entirely a fresh issue of 62.53 lakh equity shares, with a face value of ₹10 per share. The company filed its DRHP with SEBI on September 30, 2025.
The price band for this issue is set at ₹326 to ₹343 per share and the lot size for an application is 400 shares. The minimum amount of investment required by an individual investor (retail investor) is ₹2,74,400 (800 shares). The IPO will be open for subscription from May 21 to 25, 2026, on the NSE SME platform, with a tentative listing date fixed as May 29, 2026. The book-running lead managers of this issue are HEM Securities Ltd. and Share India Capital Services Pvt. Ltd., while the registrar to the issue is Purva Sharegistry (India) Pvt. Ltd.
Q-line Biotech IPO Date & Timeline
The Q-line Biotech IPO is officially set to open for subscription on May 21, 2026 and will close on May 25, 2026. The company initially filed its Draft Red Herring Prospectus (DRHP) on September 30, 2025 and has now finalized its schedule following SEBI approval. Once the subscription window allotment is expected on May 26, 2026. Following this, the company will initiate refunds and credit shares to successful investors' demat accounts on May 27, 2026. Finally, the Q-line Biotech Ltd.'s shares are tentatively scheduled to list on the stock exchanges on May 29, 2026.
Q-Line Biotech IPO Timeline
| IPO Open Date | Thu, May 21, 2026 |
| IPO Close Date | Mon, May 25, 2026 |
| Tentative Allotment | Tue, May 26, 2026 |
| Initiation of Refunds | Wed, May 27, 2026 |
| Credit of Shares to Demat | Wed, May 27, 2026 |
| Tentative Listing Date | Fri, May 29, 2026 |
Q-Line Biotech IPO Details
| Detail | Description |
|---|---|
| IPO Date | 21 to 25 May, 2026 |
| Listing Date | 29 May, 2026 |
| Face Value | ₹ 10 per share |
| Issue Price Band | ₹ 326 to ₹ 343 |
| Lot Size | 400 Shares |
| Sale Type | Fresh capital only |
| Total Issue Size | 62,53,200 shares (agg. up to ₹ 214 Cr) |
| Reserved for Market Maker | 3,13,200 shares (agg. up to ₹ 11 Cr) Hem Finlease Pvt.Ltd. |
| Fresh Issue(Ex Market Maker) | 59,40,000 shares (agg. up to ₹ 204 Cr) |
| Net Offered to Public | 59,40,000 shares (agg. up to ₹ 204 Cr) |
| Issue Type | Bookbuilding IPO |
| Listing At | NSE SME |
| Share Holding Pre Issue | 1,70,74,999 shares |
| Share Holding Post Issue | 2,33,28,199 shares |
Q-line Biotech IPO GMP (Grey Market Premium)
“Grey Market Premium” or GMP is defined as the rate at which the IPO's shares are traded in the market before they are officially listed on the stock exchange.
The Q-line Biotech IPO GMP is currently trading at ₹124, reflecting the sentiment of unofficial investors before the official listing. This premium suggests a potential listing price of ₹467, which is 36.15% above the issue price. While the Grey Market Premium is a key indicator of demand and investor appetite, it is important to remember that GMP is highly volatile and should not be the sole factor in your investment decisions.
IPO Estimated Listing Return
Based on the IPO Price of ₹343 (highest price band), the latest uploaded Grey Market Premium (GMP) of ₹112 and a lot size of 400 shares.
Q-Line Biotech GMP TREND (DAILY UPDATES)
| GMP Date | IPO Price | GMP | Last Updated |
|---|---|---|---|
| 29 May 2026 | ₹343 | ₹112 | 29 May, 202611:47 AM |
| 28 May 2026 | ₹343 | ₹125 | 28 May, 202606:01 PM |
| 27 May 2026 | ₹343 | ₹115 | 27 May, 202605:55 PM |
| 26 May 2026 | ₹343 | ₹106 | 26 May, 202612:24 PM |
| 25 May 2026 | ₹343 | ₹101 | 25 May, 202605:39 PM |
| 24 May 2026 | ₹343 | ₹125 | 25 May, 202609:58 AM |
| 23 May 2026 | ₹343 | ₹127 | 23 May, 202612:27 PM |
| 22 May, 2026 | ₹343 | ₹125 | 22 May, 202611:23 AM |
| 21 May, 2026 | ₹343 | ₹117 | 21 May, 202602:45 PM |
| 20 May, 2026 | ₹343 | ₹141 | 20 May, 202602:46 PM |
| 19 May, 2026 | ₹343 | ₹117 | 19 May, 202602:46 PM |
| 18 May, 2026 | ₹343 | ₹69 | 18 May, 202602:46 PM |
Company Background
Q-line Biotech Ltd. was incorporated on November 10, 2010, in Lucknow, Uttar Pradesh, as “POCT Services Private Limited” and then in July 2021, the company changed into its current form as a private limited company and then on February 19, 2025, it converted into a public limited company to begin its public listing procedure.
The company has established a registered office in Transport Nagar to manage its expanding operations. The company is engaged in the business of developing, manufacturing and marketing a diverse range of reagents & consumables and manufacturing, importing, distribution/supplying diagnostic equipment for different diagnostic healthcare needs.
Operations & Product Range
Q-line Biotech Ltd. operates within the healthcare and diagnostic space, providing a range of medical solutions. Through its subsidiary, the business is involved in the R&D and the distribution of surgical, medical, dental and diagnostic equipment. The product portfolio includes various accessories, kits, reagents and consumables designed for scientific and medical use. By focusing on developing substitutes for imported diagnostic products, the firm aims to cater to domestic healthcare providers and laboratories.
Facilities & Capacity
Q-line Biotech Ltd.’s operational infrastructure is centred in Lucknow, where it maintains its registered and corporate offices. Its subsidiary is authorised to manage testing houses and laboratories, providing essential research and development support. This setup allows the firm to handle the packaging, labelling and distribution of its diagnostic products. The facilities are geared toward supporting both internal research and development and commercial dealings in medical equipment.
Brands & Market Presence
Q-line Biotech Ltd. has established its market standing through the use of the brand name “Q-line Biotech”, together with the slogan “Spreading Healthiness!” This organisation maintains a targeted geographical orientation, being mainly concerned with servicing the Indian domestic market from its headquarters located in Uttar Pradesh. The operations of this business have been facilitated through a series of group companies and subsidiaries that emphasise healthcare quality, skills and diagnostic research.
Revenue Streams & Business Model
The primary revenue of Q-line Biotech Ltd. is generated through the sale of medical diagnostic equipment and consumables. Its business model integrates research and development with commercial trading and distribution. For FY25, the company reported a total revenue of ₹322.58 crore and PAT was at ₹28.13 crore. The top 10 customers of the company have contributed approx 82.17% revenue for the same period of time.
Management & Shareholding
The ownership of Q-line Biotech Ltd. is held by its five promoters, including Saurabh Garg, Amita Garg, Ayush Garg, Ajay Kumar Mahanty and Abhay Agrawal. Before the IPO, the promoters held a 96.26% stake and the promoter group held a 0.51% stake; collectively, they held a 96.77% stake in the company, but after the IPO, the promoters' shareholding will be slightly diluted as the offering is entirely a fresh issue of shares with no OFS.
Board & Key Management
The leadership of Q-line Biotech Ltd. is led by a team of experts with many years of experience. Saurabh Garg serves as the Chairman and gives strategic direction to the firm. The daily operations are managed by Saurabh Garg, the Managing Director, along with Whole-Time Directors. To ensure good governance, the board includes Independent Directors, such as Pravir Kumar, for honest oversight. Together, this team uses its knowledge to help the company grow and stay successful.
Q-Line Biotech IPO Financial Information
Latest Revenue
232.42
₹ Crore
Profit After Tax
38.69
₹ Crore
Net Worth
-0.04
₹ Crore
Total Borrowing
243.85
₹ Crore
| Period Ended | Assets | Revenue From Operations | Profit After Tax | Net Worth | Reserves & Surplus | Total Borrowing | |||
|---|---|---|---|---|---|---|---|---|---|
| 31 Dec 2025 | 561.34 | 232.42 | 38.69 | -0.04 | 212.88 | 243.85 | |||
| 31 Mar 2025 | 455.49 | 313.78 | 28.13 | 189.95 | 188.37 | 164.95 | |||
| 31 Mar 2024 | 339.25 | 203.64 | 34.44 | 161.81 | 160.24 | 96.91 | |||
| 31 Mar 2023 | 251.58 | 182.73 | 32.10 | 127.37 | 125.79 | 73.65 | |||
| Amount in ₹ Crore | |||||||||
Q-Line Biotech Key Performance Indicator
| KPI | Values |
|---|---|
| ROE | 16.88% |
| ROCE | 13.32% |
| Debt/Equity | 1.06 |
| RoNW | 16.88% |
| PAT Margin | 16.65% |
| EBITDA Margin | 27.64% |
| Price to Book Value | - |
| Pre IPO | Post IPO | |
|---|---|---|
| EPS (Rs) | 28.63 | - |
| P/E (x) | - | - |
Q-line Biotech IPO Objectives
The company intended to use the Q-line Biotech IPO proceeds for strategic purposes:
- • Funding the working capital requirement
- • Repayment or prepayment of debt (in part or in full)
- • General corporate purposes
Q-line Biotech IPO Review
Q-Line Biotech Ltd. is a niche player in the healthcare diagnostics industry, which involves offering medical kits and equipment. The firm intends to lessen its reliance on foreign sources of medical supplies by using its subsidiary for research and development activities.
Financially, the company has shown growing and healthy financial statements; as for FY25, the total revenue was reported at ₹322.58 crore and PAT was reported at ₹28.13 crore. Notably, the top 10 customers of the company have contributed ₹257.78 crore, which is 82.17% of the total revenue from operations.
However, the company's strengths lie in its long-standing presence since 2010 and its integrated approach to healthcare solutions and there are no directly comparable listed peers in India, making traditional benchmarking difficult. Overall, the Q-line Biotech IPO Review will likely depend on the company's ability to turn its R&D efforts into profitable commercial outcomes.
Conclusion
Q-line Biotech IPO is an opportunity for investors to invest in a healthcare firm with a clear focus on strengthening its working capital and reducing debt. The company is positioning itself to capture opportunities in the domestic medical diagnostic space. The company’s commitment to innovation and its established brand presence under the Q-line Biotech IPO umbrella provide a foundation for its future execution.
Frequently Asked Questions
Recommended Advisory Services
Ready to take your company public? Explore our specialized IPO advisory services tailored for Indian enterprises.
The India IPO Publication is managed by an editorial team that includes highly experienced finance journalists, market researchers and professionals from the capital markets industry who strive to create high-quality content based on credible sources. Our editors write about IPOs, capital markets, corporate news, capital-raising strategies, regulations and other business matters to ensure our audience stays updated with the latest information. We conduct detailed research and fact-check all information before publishing any content to ensure credibility.
Competitive Strengths
Established track record of over a decade in the healthcare and diagnostic sector.
Integrated research and development activities through its subsidiary to develop import-substitute medical kits.
Strategic location in Lucknow, Uttar Pradesh, providing a strong base for operations.
Focused product portfolio with a specialized range of diagnostic equipment, reagents and consumables catering to specific medical needs.
Download regulatory filings
IPO Lot Size
| Investors | No.of lots | Shares Offered | Max Bid Amount |
|---|---|---|---|
| Individual investors (Retail) (Min) | 2 | 800 | 274400 |
| Individual investors (Retail) (Max) | 2 | 800 | 274400 |
| S-HNI (Min) | 3 | 1200 | 411600 |
| S-HNI (Max) | 7 | 2800 | 960400 |
| B-HNI (Min) | 8 | 3200 | 1097600 |